AEP
48
5
PEG
50
4
LOW
53
3
EQIX
60
3
V
56
2
FTI
66
2
MSI
63
2
AFL
41
4
STX
53
3
CL
50
2
TSN
39
5
ETR
66
3
K
56
5
DUK
37
2
KR
44
4
MAS
59
3
SJM
19
5
ROST
57
3
BLK
69
3
CME
56
3
AEP
48
5
PEG
50
4
LOW
53
3
EQIX
60
3
V
56
2
FTI
66
2
MSI
63
2
AFL
41
4
STX
53
3
CL
50
2
TSN
39
5
ETR
66
3
K
56
5
DUK
37
2
KR
44
4
MAS
59
3
SJM
19
5
ROST
57
3
BLK
69
3
CME
56
3
Financhill
Back

Adaptimmune Therapeutics PLC Quote, Financials, Valuation and Earnings

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!
Sell
30

ADAP
Adaptimmune Therapeutics PLC

Last Price:
0.83
Seasonality Move:
40.93%

7 Day Trial

ALL ACCESS PASS

$ 7

U.S. Government Report Alert Tuesday

Discover the Secret Loophole

Adaptimmune Therapeutics PLC Price Quote

$0.83

Adaptimmune Therapeutics PLC Key Stats

Sell
30
Adaptimmune Therapeutics PLC (ADAP) is a Sell
Day range:
$0.79 - $0.83
52-week range:
$0.42 - $2.05
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.40
P/B ratio:
2.2%
Volume:
444.3K
Avg. volume:
1.1M
1-year change:
48.21%
Market cap:
$212.3M
Revenue:
$60.3M
EPS:
$-0.3

How Much Does Adaptimmune Therapeutics PLC Make?

Is Adaptimmune Therapeutics PLC Growing As A Company?

Adaptimmune Therapeutics PLC Stock Price Performance

What Is Adaptimmune Therapeutics PLC 52-Week High & Low?

Adaptimmune Therapeutics PLC Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Adaptimmune Therapeutics PLC?

Is Adaptimmune Therapeutics PLC Cash Flow Positive?

  • What Is ADAP Cash Flow From Operations?
    Cash flow from operations (TTM) is -$44.4M
  • What Is Adaptimmune Therapeutics PLC’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $54.4M
  • What Is Adaptimmune Therapeutics PLC’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $124.4M

Adaptimmune Therapeutics PLC Return On Invested Capital

  • Is Management Doing A Good Job?
    ADAP return on invested capital is -90.65%
  • What Is Adaptimmune Therapeutics PLC Return On Assets?
    ROA measures how assets are converting to revenues and is -24.14%
  • What Is ADAP Return On Equity?
    ROE is a measure of profitability and is -96.68%

Adaptimmune Therapeutics PLC Earnings Date & Stock Price

Adaptimmune Therapeutics PLC Competitors

Adaptimmune Therapeutics PLC Dividend Yield

Adaptimmune Therapeutics PLC Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 220.6%
Revenue: 2399.63% 186.47%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 2.74
Upside from Last Price: 229.99%

Major Shareholders

  • How many ADAP shares are owned by institutional investors?
    355.7M ADAP shares are owned by institutional investors
  • How many ADAP shares are owned by insiders?
    31.4M ADAP shares are owned by insiders